Medicine and Dentistry
Endoscopic Ultrasound
95%
Hepatocellular Carcinoma
52%
Acoustic Radiation
47%
Cystic Pancreatic Lesion
47%
Chronic Hepatitis C
47%
Neoplasm
38%
Transcatheter Arterial Chemoembolization
30%
Intraductal Papillary Mucinous Tumor
28%
Liver Biopsy
27%
Transient Elastography
27%
Diagnosis
26%
Chronic Hepatitis B
23%
Extrahepatic Bile Duct Obstruction
23%
Interferon
23%
Hypoalbuminemia
23%
Biloma
23%
Liver Cirrhosis
23%
Polyp
23%
MALT Lymphoma
23%
Branched Chain Amino Acid
23%
Cholangitis
23%
Cholestasis
23%
Hepatitis C Virus
23%
Common Bile Duct
23%
Bile Duct
23%
Nalfurafine
23%
Recurrent Disease
23%
Fibrosis
23%
Cisplatin
23%
Intraarterial Drug Administration
23%
Confocal Laser Scanning Microscopy
23%
Antiviral Therapy
23%
Combination Therapy
23%
Bevacizumab
23%
Atezolizumab
23%
Metabolic Dysfunction-Associated Steatohepatitis
23%
Ribavirin
20%
Biopsy
17%
Patatin
15%
Phospholipase
15%
Endoscopic Retrograde Cholangiopancreatography
14%
Bile Duct Cancer
12%
Pancreas Disease
11%
Prothrombin Time
11%
Liver Fibrosis
10%
Common Bile Duct Stone
9%
Vascularity
9%
Cytotechnology
9%
Tumor Biopsy
9%
Extrahepatic Bile Duct
9%
Keyphrases
Atezolizumab Plus Bevacizumab
71%
Advanced Hepatocellular Carcinoma
47%
Endoscopic Ultrasonography
28%
Intraductal Papillary mucinous Neoplasm
28%
Chronic Hepatitis B
23%
Antiretroviral Therapy
23%
Medical Ultrasonics
23%
Efficacy Predictor
23%
Liver Stiffness
23%
Biloma
23%
Bilirubin
23%
Intrahepatic Cholestasis
23%
Shear Wave Velocity
23%
Interferon-based Therapy
23%
Branched-chain Amino Acid Granules
23%
I148M
23%
PNPLA3
23%
Hepatitis B Envelope Antigen
23%
Acoustic Radiation Force Impulse Elastography
23%
Acoustic Radiation Force Impulse
23%
Stiffness Index
23%
Chronic Pruritus
23%
Nalfurafine Hydrochloride
23%
Contrast-enhanced Harmonic Endoscopic Ultrasonography
23%
Pancreatic Cyst
23%
Nutritional Status Assessment
23%
Intrahepatic Distant Recurrence
23%
Erythropoietic Protoporphyria
23%
Endoscopic Ultrasound
23%
Tremelimumab
23%
Complete Response
23%
Clinical Practice
23%
Combination Therapy
23%
Metabolic Dysfunction-associated Steatohepatitis
23%
Function Composition
23%
Atezolizumab
20%
Lenvatinib
19%
Mural Nodule
18%
Hepatitis B Surface Antigen Levels
17%
Hepatocellular Carcinoma Progression
17%
Nalfurafine
17%
Bevacizumab
17%
Fibrosis-4 (FIB-4)
15%
Nutritional Risk Index
15%
End of Treatment
14%
Transcatheter Arterial Infusion
13%
Article Use
11%
Hepatitis B e Antigen (HBeAg)
11%
Sustained Virological Response
11%
Bile Duct Tumor
11%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Bevacizumab
71%
Atezolizumab
71%
Phospholipase
39%
Combination Therapy
26%
Nonalcoholic Fatty Liver
23%
Antiviral Therapy
23%
Recurrent Disease
23%
Cisplatin
23%
Hepatitis B Antigen
23%
Interferon
23%
Extrahepatic Bile Duct Obstruction
23%
Hypoalbuminemia
23%
Chemotherapy
23%
Alpha Fetoprotein
23%
Nalfurafine
23%
Chronic Hepatitis C
23%
Branched Chain Amino Acid
23%
Alpha Tocopherol
23%
Erythropoietic Protoporphyria
23%
Tremelimumab
23%
Disease
21%
Ribavirin
20%
Aspartate Aminotransferase
19%
Lenvatinib
19%
Solid Malignant Neoplasm
19%
Diseases
17%
Alanine
15%
Focused Ion Beam
15%
Guanosine Triphosphate
11%
Serum Albumin
10%
Progression Free Survival
10%
Hepatitis B(e) Antigen
9%
Adverse Event
9%
Gamma Glutamyltransferase
8%
Recurrence Risk
7%
Epirubicin
7%
Overall Survival
6%
Erythrocyte Protoporphyrin
5%
Prothrombin
5%